

# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

14<sup>th</sup> February, 2018

### BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

### Sub: Submission of Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017

We refer to our letter dated 1<sup>st</sup> February, 2018 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017.

Please note that the company has adopted IND-AS for the first time from this financial year (2017-18).


We are enclosing herewith copy of the said Unaudited Financial Results.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED

  
KAMLESH J. LASKARI  
MANAGING DIRECTOR



Encl: As above.



**KAMRON LABORATORIES LIMITED**

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaCorporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIAPhones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON  
31<sup>ST</sup> DECEMBER, 2017**

(Rs. In lakh)

Particulars	Quarter ended on			9 Months ended on (Cumulative)	
	31-12-2017 (Unaudited)	30-09-2017 (Unaudited)	31-12-2016 (Unaudited)	31-12-2017 (Unaudited)	31-12-2016 (Unaudited)
(Refer Notes Below)					
1 Revenue from operations	165.03	167.45	522.37	622.09	1066.17
2 Other income	3.56	-	1.32	3.80	1.67
3 Total Income (1+2)	168.59	167.45	523.69	625.89	1067.84
4 Expenses					
a. Cost of Materials consumed	99.14	109.72	428.12	235.62	721.66
b. Purchases of stock-in-trade	-	-	-	140.30	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.56)	(11.08)	(3.02)	(34.31)	(58.32)
d. Employee benefits expense	42.31	37.82	39.01	111.85	119.65
e. Finance costs	15.72	9.51	0.44	40.54	23.52
f. Depreciation & amortisation expense	14.63	1.46	50.79	43.89	77.00
g. Other expenses	21.29	20.2	7.43	95.29	181.77
<b>Total Expenses</b>	<b>176.53</b>	<b>167.63</b>	<b>522.77</b>	<b>633.18</b>	<b>1065.28</b>
5 Profit / (Loss) before exceptional items and tax (3-4)	(7.94)	(0.18)	0.92	(7.29)	2.56
6 Exceptional items	-	-	-	-	-
7 Profit / (Loss) before tax (5-6)	(7.94)	(0.18)	0.92	(7.29)	2.56
8 Tax expense:					
Current tax	-	-	-	-	-
Deferred tax	-	-	-	-	-
9 Profit (Loss) for the period from continuing operations (7-8)	(7.94)	(0.18)	0.92	(7.29)	2.56
10 Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13 Profit / (Loss) for the period (9+12)	(7.94)	(0.18)	0.92	(7.29)	2.56





**KAMRON LABORATORIES LIMITED**

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaCorporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com

**KAMRON**

Particulars	Quarter ended on			9 Months ended on (Cumulative)	
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
14 <b>Other Comprehensive Income</b>	(7.94)	(0.18)	0.92	(7.29)	2.56
<i>Items that will not be reclassified subsequently to profit or loss</i>					
Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
<i>Items that will be reclassified subsequently to profit or loss</i>					
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
<b>Other Comprehensive Income, net of tax</b>					
15 <b>Total Comprehensive Income for the period (13+14)</b>	(7.94)	(0.18)	0.92	(7.29)	2.56
16 Earnings Per Share of Rs. 10 each (for continuing operations)					
- Basic	-	-	0.01	-	0.04
- Diluted	-	-	0.01	-	0.04
17 Earnings Per Share of Rs.10 each (for discontinued operations)					
- Basic	-	-	-	-	-
- Diluted	-	-	-	-	-
18 Earnings Per Share of Rs. 10 each (for discontinued & continuing operations)					
- Basic	-	-	0.01	-	0.04
- Diluted	-	-	0.01	-	0.04



# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : info@kamronlabs.com



## KAMRON

### Notes:

1	The Company adopted Indian Accounting Standards (referred to as "Ind AS") with effect from April 1, 2017 and accordingly, the financial results for the quarter ended December 31, 2017 have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
2	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
3	The Company does not have any subsidiary / associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 <sup>th</sup> February, 2018

### Reconciliation between financial results as previously reported under Indian GAAP and as per Ind AS for Quarter and Nine months ended on December 31, 2016:

(Rs. In Lakh)

Particulars	Quarter ended on 31-12-2016	Nine Months ended on 31-12-2016
Net Profit as reported under Indian GAAP	0.92	2.56
Net Profit as per Ind AS	0.92	2.56
Total Comprehensive Income as per Ind AS	0.92	2.56

For KAMRON LABORATORIES LIMITED

Date: 14<sup>th</sup> February, 2018.  
Place : Ahmedabad



*Kamlesh J. Laskari*  
KAMLESH J. LASKARI  
MANAGING DIRECTOR



# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

Corporate Office & Factory: 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

14<sup>th</sup> February, 2018

### BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

**Sub: Submission of Limited Review Report for Financial Results  
for the quarter ended on 31<sup>st</sup> December, 2017**

We refer to our letter dated 14<sup>th</sup> February, 2018 enclosing Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017

We are now enclosing herewith Limited Review Report dated 14<sup>th</sup> February, 2018 for Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

for KAMRON LABORATORIES LIMITED

*Kamlesh J. Laskari*

KAMLESH J. LASKARI  
MANAGING DIRECTOR



Encl: As above.

**LIMITED REVIEW REPORT****Review Report to the Board of Directors of Kamron Laboratories Ltd.**

We have reviewed the accompanying statement of unaudited financial results of Kamron Laboratories Ltd. ("the Company") for the Quarter and *Nine Months* ended 31<sup>st</sup> December, 2017 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the financial results and other financial information for the Quarter and *Nine Months* ended December 31, 2017 which have been presented solely based on the financial information compiled by the Management.

For RANGWALA & CO  
Chartered Accountants  
(Firm's Registration No. 115833W)



  
(Z.E. RANGWALA)  
Partner  
(Membership No. 031268)

Place of signature: AHMEDABAD  
Date: 14<sup>th</sup> February, 2018

# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

**Regd. Office:** Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

**Corporate Office & Factory:** 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



**(Machine Readable Format)**

14<sup>th</sup> February, 2018

## **BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**Company Code No. 524604**

Dear Sirs,

### **Sub: Submission of Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017**

We refer to our letter dated 1<sup>st</sup> February, 2018 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 31<sup>st</sup> December, 2017.

Please note that the company has adopted IND-AS for the first time from this financial year (2017-18).

We are enclosing herewith copy of the said Unaudited Financial Results.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

**For KAMRON LABORATORIES LIMITED**

**KAMLESH J. LASKARI  
MANAGING DIRECTOR**

Encl: As above.

# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

**Regd. Office:** Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel, S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

**Corporate Office & Factory:** 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.), Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

### STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31<sup>ST</sup> DECEMBER, 2017

(Rs. In lakh)

Particulars		Quarter ended on			9 Months ended on (Cumulative)	
		31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	<b>Revenue from operations</b>	165.03	167.45	522.37	622.09	1066.17
2	<b>Other income</b>	3.56	-	1.32	3.80	1.67
3	<b>Total Income (1+2)</b>	<b>168.59</b>	<b>167.45</b>	<b>523.69</b>	<b>625.89</b>	<b>1067.84</b>
4	<b>Expenses</b>					
	a. Cost of Materials consumed	99.14	109.72	428.12	235.62	721.66
	b. Purchases of stock-in-trade	-	-	-	140.30	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.56)	(11.08)	(3.02)	(34.31)	(58.32)
	d. Employee benefits expense	42.31	37.82	39.01	111.85	119.65
	e. Finance costs	15.72	9.51	0.44	40.54	23.52
	f. Depreciation & amortisation expense	14.63	1.46	50.79	43.89	77.00
	g. Other expenses	21.29	20.2	7.43	95.29	181.77
	<b>Total Expenses</b>	<b>176.53</b>	<b>167.63</b>	<b>522.77</b>	<b>633.18</b>	<b>1065.28</b>
5	Profit / (Loss) before exceptional items and tax (3-4)	(7.94)	(0.18)	0.92	(7.29)	2.56
6	Exceptional items	-	-	-	-	-
7	Profit / (Loss) before tax (5-6)	(7.94)	(0.18)	0.92	(7.29)	2.56
8	Tax expense:					
	Current tax	-	-	-	-	-
	Deferred tax	-	-	-	-	-
9	Profit (Loss) for the period from continuing operations (7-8)	(7.94)	(0.18)	0.92	(7.29)	2.56
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit / (Loss) for the period (9+12)	(7.94)	(0.18)	0.92	(7.29)	2.56



# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

**Regd. Office:** Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel, S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

**Corporate Office & Factory:** 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.), Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

Particulars		Quarter ended on			9 Months ended on (Cumulative)	
		31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
14	<b>Other Comprehensive Income</b>	<b>(7.94)</b>	<b>(0.18)</b>	<b>0.92</b>	<b>(7.29)</b>	<b>2.56</b>
	<i>Items that will not be reclassified subsequently to profit or loss</i>					
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	<i>Items that will be reclassified subsequently to profit or loss</i>					
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Other Comprehensive Income, net of tax</b>					
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>(7.94)</b>	<b>(0.18)</b>	<b>0.92</b>	<b>(7.29)</b>	<b>2.56</b>
16	Earnings Per Share of Rs. 10 each (for continuing operations)					
	- Basic	-	-	<b>0.01</b>	-	<b>0.04</b>
	- Diluted	-	-	<b>0.01</b>	-	<b>0.04</b>
17	Earnings Per Share of Rs.10 each (for discontinued operations)					
	- Basic	-	-	-	-	-
	- Diluted	-	-	-	-	-
18	Earnings Per Share of Rs. 10 each (for discontinued & continuing operations)					
	- Basic	-	-	<b>0.01</b>	-	<b>0.04</b>
	- Diluted	-	-	<b>0.01</b>	-	<b>0.04</b>

# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

**Regd. Office:** Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

**Corporate Office & Factory:** 737, Rakanpur, Sola-Santej Road, Tal. Kalol (N. G.),  
Dist. Gandhinagar, Gujarat-382 721, INDIA

Phones: (02764) 286549/ 286559 Fax : (02764) 286038 E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## Notes:

1	The Company adopted Indian Accounting Standards (referred to as “Ind AS”) with effect from April 1, 2017 and accordingly, the financial results for the quarter ended December 31, 2017 have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
2	The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.
3	The Company does not have any subsidiary / associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 <sup>th</sup> February, 2018

## Reconciliation between financial results as previously reported under Indian GAAP and as per Ind AS for Quarter and Nine months ended on December 31, 2016:

(Rs. In Lakh)

Particulars	Quarter ended on 31-12-2016	Nine Months ended on 31-12-2016
<b>Net Profit as reported under Indian GAAP</b>	<b>0.92</b>	<b>2.56</b>
Net Profit as per Ind AS	0.92	2.56
<b>Total Comprehensive Income as per Ind AS</b>	<b>0.92</b>	<b>2.56</b>

For KAMRON LABORATORIES LIMITED

Date: 14<sup>th</sup> February, 2018.  
Place : Ahmedabad

**KAMLESH J. LASKARI**  
MANAGING DIRECTOR